The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | PREEMPT CRC: blood-based test for colorectal cancer screening
Aasma Shaukat, MD, MPH, NYU Grossman School of Medicine, New York, NY, discusses the results of PREEMPT CRC (NCT04369053), a large population-based study on a novel blood test for detecting colorectal cancer. Dr Shaukat notes that the study, conducted at 200 centers across the US, met all its primary endpoints, demonstrating the clinical validity of the blood test. The study’s findings show that the blood test has a high sensitivity and specificity for detecting colorectal cancer, with a positive predictive value of 15.5% for advanced colorectal neoplasia This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
